Opinion|Videos|April 28, 2025
FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels
Experts discuss FDA-approved therapies for high lipoprotein(a) [Lp[a]) levels, their benefits and shortcomings, the frequency of their use in health plans, emerging therapies in the pipeline, and the expected timeline for associated data release.
Advertisement
Video content above is prompted by the following:
- What therapies for high Lp(a) levels are currently approved by the FDA?
- What benefits and shortcomings (eg, cost, time) are associated with this therapy?
- How frequently is this therapy used in the health plans you work with?
- What therapies are in the pipeline?
- When do we expect associated data to be released?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
2
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
3
The Changing Treatment Landscape of IPF and PPF: Toby Maher, MD, PhD
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5
